ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Azitra, Inc. (AZTR) stock surged +0.81%, trading at $0.35 on AMEX, up from the previous close of $0.34. The stock opened at $0.36, fluctuating between $0.35 and $0.37 in the recent session.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Employees | 12 |
Beta | -2.11 |
Sales or Revenue | N/A |
5Y Sales Change% | 9.885% |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |